Recombinant Human CCL23 Protein

Name: Recombinant Human CCL23 Protein
Brand: Beta LifeScience
SKU: BL-1795NP
Availability: InStock

BL-1795NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Chemokines and receptors, Cytokines, Cytokines and growth factors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human C-C Motif Chemokine 23 is produced by our E.coli expression system and the target gene encoding Arg46-Asn120 is expressed.
Accession	P55773
Synonym	C-C Motif Chemokine 23; CK-Beta-8; CKB-8; Macrophage Inflammatory Protein 3; MIP-3; Myeloid Progenitor Inhibitory Factor 1; MPIF-1; Small-Inducible Cytokine A23; CCL23; MIP3; MPIF1; SCYA23
Gene Background	Human Chemokine (C-C Motif) Ligand 23 (CCL23) is a small cytokine belonging to the CC chemokine family. CCL23 is also known as myeloid progenitor inhibitory factor MPIF-1, CK8 and SCYA23. CCL23 cDNA encodes a 120 amino acid residue precursor protein with a putative 21 amino acid residue signal peptide that is cleaved to generate a 99 amino acid residue mature CCL23 (amino acids 22 -120). Additional N-terminal Processing of the 99 amino acid residue variant can generate a 75 amino acid residue peptide (amino acid 46-120) that is significantly more active than the 99 amino acid residue variant. CCL23 binds to CCR1 with high affinity and has chemotactic activity for monocytes, dendritic cells, and osteoclast precursors. CCL23 enhances angiogenesis of endothelial cells, but reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages.
Molecular Mass	8.7 KDa
Apmol Mass	11 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 250mM NaCl, pH 7.2.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Shows chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils, but not for activated lymphocytes. Inhibits proliferation of myeloid progenitor cells in colony formation assays. This protein can bind heparin. Binds CCR1. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are more potent chemoattractants than the small-inducible cytokine A23.
Subcellular Location	Secreted.
Protein Families	Intercrine beta (chemokine CC) family
Database References	HGNC: 10622 OMIM: 602494 KEGG: hsa:6368 UniGene: Hs.169191
Tissue Specificity	High levels in adult lung, liver, skeletal muscle and pancreas. Moderate levels in fetal liver, adult bone marrow and placenta. The short form is the major species and the longer form was detected only in very low abundance. CCL23(19-99), CCL23(22-99), CC

Gene Functions References

CCL23 is posttranslationally modified by trypsin-like serine proteases and CCL23(47-117) might be a major active form of CCL23 in nasal polyps with chronic rhinosinusitis. PMID: 26560043
The coexistence of diabetes and oxidative stress independently affected CCL23 levels, while the presence of Cardiovascular disease and inflammation had no impact on its concentrations. PMID: 24995525
ADAMTS 8, CCL23, and TNFSF15 are implicated in anti-angiogenic activities PMID: 24384427
Data show CCL23 stimulates chemotaxis of human THP-1 monocytes and enhances release of MMP-2, and suggest it plays a role in atherogenesis. PMID: 21656154
Overproduction of CCL23 in nasal polyps might contribute to the pathogenesis of eosinophilic chronic rhinosinusitis with nasal polyps PMID: 21497884
Patients with systemic sclerosis who had elevated CCL23 levels had shorter disease duration, and a higher frequency of pulmonary arterial hypertension. Serum CCL23 level was increased in early phase of disease and could be a marker for disease activity. PMID: 20824279
Fresh eosinophils contained trace amounts of CCL23 protein. CCL23 was significantly released into the supernatant when the eosinophils were stimulated with GM-CSF or IL-5 but not with IFN-gamma or immobilized sIgA. PMID: 21646793
independently associated with coronary atherosclerosis PMID: 20187767
CKbeta8 transduces the chemotaxis signal through the G(i)/G(o) protein, phospholipase C, protein kinase C delta and NF-kappaB. PMID: 19951712
CCL23 promoted chemotactic migration and differentiation of endothelial cells, and neovascularization in the chick chorioallantoic membrane PMID: 15927850
May play a direct role in angiogenesis via upregulation of matrix metalloproteinase (MMP)-2 expression. PMID: 16378600
Collectively, these data suggest a link between the inducible phenotype of CCL23 expression in monocytes by the prototype Th2 molecule pair IL-4/STAT6 and the increased number of CCL23-expressing cells in skin of atopic dermatitis patients. PMID: 17371990
A peptide ligand termed SHAAGtide is cleaved from CCL23; is itself an attractant of monocytes and neutrophils in vitro; recruits leukocytes in vivo; is more potent than other natural agents with activity for FPRL1; receives authors' designation "CCR12." PMID: 17513790
This protein may participate in the malignant progression of certain human cancer cells that overexpress ErbB2 through the transactivation of ErbB2 tyrosine kinase. PMID: 18258606
CCL23, M-CSF, TNFRSF9, TNF-alpha, and CXCL13 are predictive of rheumatoid arthritis disease activity and may be useful in the definition of disease subphenotypes and in the measurement of response to therapy in clinical studies. PMID: 18668547
these findings suggest that CCL23 results in up-regulation of KDR/flk-1 receptor gene transcription and protein expression and that KDR/Flk-1 up-regulation induced by CCL23 may contribute to potentiation of VEGF action in angiogenesis. PMID: 19265684

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.